SINCO PHARMA (06833) announced that Mr. Huang Xiangbin has resigned from his positions as Chairman of the Board, Executive Director, Chairman of the Board Nomination Committee, and the company's authorized representative under Rule 3.05 of the Hong Kong Stock Exchange's Listing Rules, effective April 30, 2026. Mr. Huang cited his intention to dedicate more time and effort to his other business commitments. Mr. Huang Zhijian has been appointed as the authorized representative, effective from the same date. Mr. Huang Zhijian currently serves as Vice Chairman of the Board and Executive Director.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments